Background aims. Cirrhosis, end-stage liver disease, is caused by different mechanisms of injury, associated with persistent infl ammation. Galectin-3 is an important regulator of fi brosis that links chronic infl ammation to fi brogenesis. We investigated the role of bone marrow cell (BMC) transplantation in chronic infl ammation and hepatic fi brosis. Methods . Liver cirrhosis was induced by administration of carbon tetrachloride and ethanol to wild-type C57BL/6 or bone marrow chimeric mice. Bone marrow chimeras were generated by lethal irradiation and transplantation with BMC obtained from green fl uorescent protein (GFP ϩ )donors. Wild-type cirrhotic mice were transplanted with BMC without irradiation. Livers from chimeras and cirrhotic transplanted mice were obtained for evaluation of infl ammation, fi brosis and regulatory factors [galectin-3, matrix metallopeptidase (MMP)-9, tissue inhibitor of metalloproteinase (TIMP)-1 and transforming growth factor (TGF)-β ].
Introduction
Cirrhosis is the end stage of many chronic liver diseases and represents a therapeutic challenge world-wide (1 -3) . The development of cirrhosis is initiated after repeated insults that cause chronic liver tissue damage, consequently inducing fi brosis and nodular regeneration of liver cells. This process is frequently associated with an infl ammatory response and the activation of hepatic stellate cells, known as the most important source of extracellular matrix (ECM) production, along with different subtypes of myofi broblasts, such as fi brogenic cells from the epithelial-to-mesenchymal transition, periportal fi brocytes, and bone marrowderived fi brocytes that synthesize ECM proteins (4, 5) . Persistent noxious stimuli lead to chronic activation of macrophages and synthesis of molecules that promote fi brogenesis, such as galectin-3, a lectin that regulates a wide variety of biologic phenomena, establishing a link between chronic infl ammation and fi brogenesis (6).
It has been shown that galectin-3 activates and stimulates the proliferation of myofi broblasts as well as increases their synthesis of collagen (7) . Furthermore, galectin-3 expression has been associated with the development of fi brosis in a variety of organs, such as the kidney, liver, gut and heart (8, 9) . As a result of the persistent stimulus to fi brogenesis, with increased galectin-3 expression, profound alterations in the liver architecture occur, modifying the relationship between stromal components, vessels and hepatocytes, ultimately characterizing liver cirrhosis (10).
Liver transplantation is the only effective treatment available for patients with cirrhosis presenting chronic hepatic failure (2, 11) , and it remains a high-risk procedure limited by the availability of donated organs. In this context, the development of new therapeutic strategies for liver failure is necessary. Stem cell therapy has emerged as a potential tool in the treatment of liver disease (12) . In recent years, many experimental studies have been carried out to evaluate the therapeutic effi cacy of stem cells in models of acute hepatic injuries (13 -24) . Although the results have been promising, further studies on models of chronic liver disease are necessary. There is also a need to understand the mechanisms by which stem cell therapy can be benefi cial in treating liver disease (25) .
Cell therapy can act through a variety of mechanisms, either directly or indirectly by secretion of molecules that can counteract fi brogenesis, such as soluble mediators and metalloproteinases (21, 26) . The present study evaluated the effects of bone marrow cells (BMC) transplanted in mice with cirrhosis induced by long-term administration of carbon tetrachloride and ethanol (CCl 4 ϩ EtOH). Our results demonstrate the therapeutic potential of BMC in a well-established cirrhosis model and reinforce the idea that galectin-3 may be a potential intervention target in the treatment of liver fi brosis.
Methods

Ethics statement
Prior to undertaking the studies described here, approval for all the experiments using mice was obtained from the Gon ç alo Moniz Research Center (CPqGM), Funda ç ã o Oswaldo Cruz (FIOCRUZ; Salvador, Bahia, Brazil) Ethics Committee and certifi ed as 001/2007, protocol number 24.
Animals
Three-week-old male C57BL/6 wild-type and female enhanced green fl uorescent protein (eGFP)-transgenic mice were used as recipients and donors of BMC, respectively. All the animals, weighing between 20 and 23 g, were raised and maintained at the Gon ç alo Moniz Research Center/ FIOCRUZ, in rooms with a controlled temperature (22 Ϯ 2 ° C) and humidity (55 Ϯ 10%) environment under continuous air renovation conditions. Animals were housed in a 12-h light/12-h dark cycle (6.00 -18.00) with rodent diet and water ad libitum .
Generation of bone marrow chimeras
C57BL/6 female mice were irradiated with 6 Gy for depletion of BMC ( Figure 1A ) in a 137 Cesium source irradiator (CisBio International, Gif Sur Yvette France). BMC were obtained from the femurs and tibiae of male eGFP transgenic mice and used to reconstitute irradiated mice. The mononuclear cells were purifi ed by centrifugation in Ficoll gradient at 1000 g for 15 min (Histopaque 1119 and 1077; 1:1; Sigma, St Louis, MO, USA). After two washings in Dulbecco ' s modifi ed Eagle medium (DMEM) medium (Sigma), the cells were fi ltered and resuspended in saline. Each irradiated mouse received an injection of 10 7 cells. Two weeks later, representative animals were killed and BMC were harvested to confi rm repopulation by donor cells using fl ow cytometry analysis.
Induction of hepatic injury and cirrhosis
Experimental cirrhosis was induced in wild-type and chimeric mice by administration of 0.2 mL 20% CCl 4 dissolved in a mineral oil solution (Merck, Darmstadt, Germany) and diluted in olive oil through gavage twice a week, combined with 5% (v/v) ethanol (EtOH) in the drinking water ( Figure 1B ). Control mice were maintained in the same housing conditions as the experimental groups. Groups of animals were killed for evaluation after periods of 24 days, 2 -3 months and 5 -6 months.
Morphologic and morphometric hepatic analyzes
Mice under anesthesia were perfused through the heart with 50 mL phosphate-buffered saline (PBS) followed by 200 mL paraformaldehyde at 4 ° C. Liver slices were fi xed in 10% formalin and embedded in paraffi n. Five micrometer-thick sections were stained with either hematoxylin-eosin (H&E) for histologic analysis and to quantify infl ammation, or picrosirius red to quantify fi brosis. Analyzes were performed on whole liver sections after slide scanning using the Aperio ScanScope system (Aperio Technologies, Vista, CA, USA). The images were analyzed used the Image Pro program (version 7.0; Media Cybernetics, San Diego, CA, USA). A mean area of 54 636 978 μ m 2 /mouse was analyzed.
Cirrhosis was defi ned by the presence of hepatic cell nodules delimited by fi brosis occupying most of the liver parenchyma. The morphologic parameters analyzed were presence of steatosis, ballooning cells, apoptosis, necrosis, Mallory -Denk bodies, ductular proliferation and infl ammation (portal and acinar). These parameters were classifi ed according to intensity in fi ve grades, ranging from 0 to 4.
Transplantation of BMC to wild-type C57BL/6 mice
Six months after treatment with CCl 4 ϩ EtOH, the administration of these drugs was suspended and the wild-type C57BL/6 mice were submitted to BMC transplantation ( Figure 1B ). BMC were obtained from femurs and tibiae of C57BL/6 eGFP transgenic mice. BMC were purifi ed by centrifugation in a Ficoll gradient (Histopaque 1119 and 1077, 1:1; Sigma-Aldrich, St Louis, MO, USA) at 1000 g for 15 min. BMC were suspended in saline and injected into the cirrhotic wild-type C57BL/6 mice. The isolated BMC were analyzed using fl ow cytometry with the following conjugated antibodies from Becton Dickinson (San Diego, CA, USA): stem cell antigen-1(Sca-1) -phycoerythrin (PE)/Cyanine (Cy)5, CD45 -Allophycocyanin(APC), CD44 -PE, CD34 -PE, CD11b -PE and CD117 -PE. Acquisition and analysis were performed in a FACScalibur fl ow cytometer (Becton Dickinson One or three doses of 3 ϫ 10 7 cells/mouse were administered intravenously, via the retro-orbital plexus, with 7 days between injections. Control cirrhotic mice received saline injections at similar intervals. Mice were killed at various time-points after cell treatment.
Immunofl uorescence analysis
The 5-μ m frozen sections obtained from the livers of mice were fi xed in 4% cold paraformaldehyde in a 0.1 M phosphate buffer. The presence of transplanted GFP ϩ BMC in the liver tissue was analyzed using direct fl uorescence microscopy. The following antibodies were used: anti-cytokeratin-18, diluted 1:100 (Santa Cruz Biotechnology, Santa Cruz, California, USA); anti-CD45, diluted 1:100 (Caltag, Buckingham, UK); anti-albumin, diluted 1:400 (DAKO, Glostrup, Denmark); and antigalectin-3, diluted 1:50 (Santa Cruz Biotechnology). Nuclei were counterstained with 4,6-dismidino-2-phenylindole (VectaShield hard set mounting Figure 1 . A schematic illustration of the experimental design. Generation of bone marrow chimeras and hepatic injury (A). C57BL/6 female mice were irradiated (6 Gy) and transplanted with BMC obtained from GFP ϩ donors (10 7 cells/mouse). Chimeric mice were submitted to a cirrhosis-induction protocol with administration of CCl 4 ϩ EtOH, and were killed 1 month ( n ϭ 5) or 6 months ( n ϭ 5) later. Control chimeric mice remained without injury at the same time-points ( n ϭ 10). Induction of experimental liver cirrhosis and therapy with BMC (B). Groups of mice were treated with CCl 4 ϩ EtOH. Normal controls were maintained in the same housing conditions. Mice were killed for morphologic evaluations and characterization of the experimental model ( n ϭ 4/time-point) after different periods of CCl 4 ϩ EtOH administration (24 days and 2, 3, 5 and 6 months). Cirrhotic mice (treated for 6 months with CCl 4 ϩ EtOH) were transplanted with BMC or injected with saline and killed 2 months later for morphometric, immunofl uorescence and qRT-PCR studies ( n ϭ 5 -8 mice/group).
Results
Cirrhosis induction in mice chronically treated with CCl 4 ϩ EtOH
Chronic administration of CCl 4 ϩ EtOH caused progressive morphologic alterations in the liver. After 6 months of repeated administration of CCl 4 ϩ EtOH, the livers exhibited morphologic alterations, such as a nodular surface and brownish coloring (Figure 2A , B). The normal parenchyma was replaced by regenerative nodules ( Figure 2C , D) measuring 453 Ϯ 199 μ m in diameter (ranging from 196 to 770 μ m) delimited by fi brous septa. Vascular alterations, including portal vein dilation, were observed ( Figure 2A ). The survival medium with DAPI H-1500; Vector Laboratories, Burlingame, CA, USA). The presence of fl uorescent cells was observed using an AX70 microscope with an epifl uorescence system plus grid to enhance the fl uorescence resolution (Optigrid, structured light imaging system; Thales Optem Inc., Olympus, Center Valley, PA, USA), using appropriate fi lters (Olympus) in a FluoView1000 confocal microscope (Olympus, Optigrid, Fairport, NY, USA). Quantifi cation of galectin-3 ϩ cells, autofl uorescent cells and type I collagen were performed in 10 random fi elds per section. Cell images were captured using 400 ϫ magnifi cation and analyzed using Image Pro Plus software.
Real-time -polymerase chain reaction
Total RNA was isolated from the livers using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and the concentration was determined by photometric measurement. A high-capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA) was used to synthesize cDNA from 1 μ g RNA, in accordance with manufacturer ' s recommendations. Real-time -polymerase chain reaction (qRT-PCR) assays were performed to detect the expression levels of transforming growth factor (TGF)-β 1, tissue inhibitor of metalloproteinase (TIMP)-1 and matrix metallopeptidase (MMP)-9 genes. qRT-PCR amplifi cation mixtures contained 20 η g template cDNA, and Taqman master mix (10 μ L) (Applied Biosystems) probes for TGF-β (Mm00441724_m1), TIMP-1 (Mm00441818_m1) and MMP-9 (Mm00442991_m1) in a fi nal volume of 20 μ L. All reactions were run in duplicate on an ABI7500 sequence detection system (Applied Biosystems) under standard thermal cycling conditions. The mean cycle threshold ( Ct ) values from duplicate measurements were used to calculate expression of the target gene, with normalization to an internal control glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using the 2 -D Ct formula. Experiments with coeffi cients of variation greater than 5% were excluded. A no-template control (NTC) and noreverse transcription controls (No-RT) were also included.
Statistical analysis
Data were analyzed using a Student ' s t -test or ANOVA , followed by Newman -Keuls (TGF-β and morphometry) or Tukey (qRT-PCR) tests, using Prism Software (version 5.0; GraphPad Software, San Diego, CA, USA). Differences were considered signifi cant if P was equal to or less than 0.05. ( Figure 2G ). Ductular cell proliferation was observed in connective tissue ( Figure 2G ).
Foci of infl ammatory cells were seen within the fi brous septa ( Figure 2H ) Immunostaining for F4/80 ϩ , a macrophage cell marker, demonstrated that many of the infl ammatory cells were macrophages ( Figure 3A) . Among these cells, some showed an abundant clear brown cytoplasm. These cells had autofl uorescent granules, were positive for the F4/80 ϩ marker and also for galectin-3 ( Figure  3B, C) . These cells were observed in greater quantities at later time-points ( Figure 3D -F) , although some F4/80 ϩ cells remained negative for galectin-3 ( Figure 3C, detail) .
Migration of BMC to injured liver
In order to evaluate the recruitment of BMC during the development of cirrhosis, bone marrow chimeras were generated and submitted to treatment with CCl 4 ϩ EtOH or remained as uninjured controls. Acute and chronic hepatic injury induced by CCl 4 ϩ EtOH resulted in an increase in the recruitment of BMC to the liver, compared with control animals. GFP ϩ cell numbers were found to be 2-fold increased in acutely during 6 months of CCl 4 ϩ EtOH administration was about 70% (37/53).
Short-term administration (24 days) of CCl 4 ϩ EtOH induced hepatic cell necrosis and a mixed infl ammatory infi ltrate with a predominance of mononuclear cells, especially in centrilobular areas (data not shown). At this time-point, mild hepatocellular ballooning without steatosis was observed. Some incomplete fi brous septa linking vascular structures were also observed. After a longer period of CCl 4 ϩ EtOH administration (2 -5 months), the normal liver architecture was partially replaced by nodules of regenerating liver cells surrounded by fi brous septa. At this time-point, a mild ductular proliferation was present within portal tracts, as well as in fi brous septa (data not shown).
Cirrhosis was established after 6 months of continuous CCl 4 ϩ EtOH administration, and characterized by a diffuse liver alteration with fi brous tissue completely surrounding nodules of regenerative hepatocytes, resulting in profound alteration of the liver architecture ( Figure 2C, D) . Some cirrhotic nodules showed microvacuolar hepatocellular steatosis and foci ballooning cells ( Figure 2E, F) , and hyaline Mallory -Denk bodies were frequently observed Figure 3 . Presence of galectin-3 ϩ cells during the establishment of experimental cirrhosis. Phagocytic cells found in infl ammatory infi ltrates had deposits of autofl uorescent material (red) and were also positive for F4/80 (green) (A) (1200 ϫ ). Picrosirius staining visualized by fl uorescence microscopy showed the presence of autofl uorescent cells (yellow) associated with fi brous septa (red) (B) (100 ϫ ). Most galectin-3 ϩ (red) cells co-stained with F4/80 (green; C) (1200 ϫ ) and a few galectin-3 ϩ cells were F4 -80 -(C, detail). Immunofl uorescence staining with anti-galectin-3 (red) and DAPI (blue) in liver sections of non-injured mice (D) (400 ϫ ) and CCl 4 ϩ EtOH-treated mice formice signifi cantly increased at later time-points ( Figure 4F) .
In order to investigate whether BMC migrate to the livers of non-irradiated mice with established cirrhosis, the animals were transplanted intravenously with 3 ϫ 10 7 bone marrow mononuclear cells obtained from GFP transgenic mice. GFP ϩ BMC were found in the liver sections of cirrhotic mice 3 days after transplantation ( Figure  5A ). At this time-point, GFP ϩ cells were mostly small and round in shape and were found in portal area tracts. One week after transplantation, GFP ϩ cells, mostly with an elongated shape, were found within the fibrous septa ( Figure 5B ). GFP ϩ cells were not seen in the liver sections of mice analyzed 1 and 2 months after transplantation (data not shown).
Effects of BMC transplantation in livers of cirrhotic mice
To evaluate the effects of the transplanted cells into non-irradiated cirrhotic mice, liver sections were analyzed 2 months after the therapy with BMC. Mice were submitted to a 3-week protocol, with 1-weekly intravenous injections of 3 ϫ 10 7 cells. A reduction in fi brosis was observed in the BMCtreated mice, compared with controls ( Figure 5C, D) , which was confi rmed by morphometric evaluation ( Figure 6A) . A marked reduction in collagen I was observed in the fi brous septa of livers from BMCtreated mice, compared with controls ( Figure 6B ). In addition, the number of infl ammatory and large autofl uorescent cells signifi cantly decreased after BMC therapy ( Figure 6C, D) . In contrast with these results, transplantation of BMC to mice that were still receiving CCl 4 ϩ EtOH between 4 and 6 months of the protocol did not lead to lower levels of fi brosis, compared with mice injected with saline (data not shown).
To investigate the mechanisms by which BMC therapy resulted in a reduction of fi brosis, we tested whether BMC transplantation modulated the production of the fi brogenic cytokine TGF-β . Liver TGF-β mRNA levels in cirrhotic mice were increased compared with normal controls. However, no differences were observed in the group treated with BMC compared with saline-treated cirrhotic mice, as investigated by qRT-PCR analysis ( Figure  6E ). Two additional factors associated with fi brosis, TIMP-1 and MMP-9, were also evaluated at the gene expression level. The same pattern of expression as found at the TGF-β mRNA level was also observed with TIMP-1, a pro-fi brogenic factor. The expression of MMP-9, an anti-fi brogenic factor, was injured livers compared with uninjured controls ( Figure 4B, F) , and the number was three times greater in chronically injured mice ( Figure 4C -F) . In the non-injured control group, GFP ϩ cells were found predominantly in sinusoids ( Figure 4A ).
However, in acutely injured livers GFP ϩ cells were seen around the central vein in the hepatic lobules ( Figure 4C ), whereas in chronically injured livers they were found mainly within the fi brous septa ( Figure 4D ). Few cells co-expressing GFP and albumin could be found in the hepatic parenchyma in chronically injured mice ( Figure 4E) , with none found in uninjured controls. The number of GFP ϩ cells in the parenchyma of chimeric Immunofl uorescence for detection of GFP (green), albumin (red) and nuclear counterstaining with DAPI (blue). Bone marrow GFP ϩ positive cells were found in small numbers in sinusoids of non-injured chimeras (A) (400 ϫ ) and at greater numbers in perivascular regions of acutely injured chimeras after 30 days of CCl 4 ϩ EtOH treatment (B) (400 ϫ ). Most infi ltrating GFP ϩ cells (green) were found in periportal infl ammatory infi ltrates at 30 days of CCl 4 ϩ EtOH treatment and co-stained with CD45 (red) (C, detail) (200 ϫ ). At 6 months of CCl 4 ϩ EtOH treatment, GFP ϩ cells (green) were mostly found in fi brous septa and some presented autofl uorescent cytoplasmic deposits (red) (D) (200 ϫ ). Rarely, hepatocytes co-stained with albumin (red) and GFP (green) were visualized after 6 months of CCl 4 ϩ EtOH treatment (E) (800 ϫ ). The GFP ϩ cells were quantifi ed in non-injured, 30-day injured and 6-months injured chimeras (F). Data are represented as the means Ϯ SEM of fi ve animals per group. * P Ͻ 0.05 (F).
liver cirrhosis, providing a useful tool for studying mechanisms of fi brogenesis and fi brosis regression, as well as for the development of novel potential therapies.
The bone marrow mononuclear cell fraction tested in our study comprises a number of cell types and therefore additional studies are needed to identify which cell populations are responsible for the benefi cial effects observed. However, despite being a heterogeneous population, transplantation of BMC is already a well-established procedure in medical practice, which helps translation of the results to clinical studies. In this regard, initial clinical studies using autologous BMC transplantation in patients with chronic liver disease have been conducted by our group and others (25, 27) .
Different populations of bone marrow-derived cells have been implicated in both the development as well as the regression of cirrhosis (21,28). The establishment of chronic liver injury and its progression to cirrhosis involves the activation of hepatic stellate cells, which are converted into fi broblasts and myofi broblasts and become the main source of ECM in liver fi brosis. Furthermore, the potential role of other fi broblast subpopulations has been described, such as fi brogenic cells from the epithelial-to-mesenchymal transition, periportal fi brocytes and bone marrowderived cells (5). The role of BMC as another source found to be similar among all groups analyzed (data not shown).
Reduction of galectin-3 expression after BMC treatment in livers of cirrhotic mice
The expression of galectin-3 in the livers of cirrhotic mice was evaluated. Galectin-3 ϩ cells were observed mainly in portal tracts and in fi brous septa in cirrhotic mice treated with saline ( Figure 7A) , whereas in the livers of BMC-treated cirrhotic mice galectin-3 ϩ cells were observed only in portal tracts ( Figure 7B ). Morphometric analysis revealed a marked decrease in the number of galectin-3 ϩ cells in the livers of mice 2 months after BMC transplantation, compared with saline-treated cirrhotic controls ( P Ͻ 0.0001; Figure 7C ).
Discussion
A growing number of reports have shown that BMC transplantation mitigates liver damage in acute experimental models (13 -16,18 -20,22) . In the present study we report the benefi cial effects of BMC transplantation in an experimental model of cirrhosis, induced by chronic administration of CCl 4 ϩ EtOH. C57BL/6 mice chronically receiving CCl 4 ϩ EtOH developed morphologic alterations that characterize Figure 5 . BMC migrate to cirrhotic liver and promote fi brosis reduction. Mice were transplanted intravenously with BMC after the establishment of cirrhosis and were killed 1 or 7 days later for fl uorescence microscopy analysis. For visualization of GFP ϩ cells (green), sections were mounted with nuclear counterstaining with DAPI (blue). Small, round-shaped GFP ϩ cells were seen 1 day after the transplantation (A and detail), while GFP ϩ with elongated shapes were seen in fi brous septa after 7 days (B and detail). Picrosirius red staining for detection of collagen in liver sections of saline-treated © and BMC-treated (D) mice.
Schistosoma mansoni (31). Previous reports have indicated that the fi nding of bone marrow-derived hepatocytes may be the result of fusion of BMC with hepatocytes (32). As we did not observe the presence of bone marrow-derived hepatocytes 2 months after cell transplantation, the contribution of these cells to hepatocyte renewal was not found to be relevant to the repair process.
BMC were found mainly in the fi brous septa of BMC-transplanted cirrhotic mice, and promoted regression of fi brosis, suggesting the potential antifi brogenic role of BMC by accelerating the process of fi brosis regression that was observed naturally 2 months after the withdrawal of CCl 4 ϩ EtOH. This result was only achieved in the groups of mice treated with repeated injections of BMC over a 3-week period, and after the withdrawal of CCl 4 ϩ EtOH. We were unable to detect any improvement in liver fi brosis when mice were treated with BMC during the cirrhosis induction protocol. In another study, of liver fi brocytes during fi brogenesis has been studied before by Higashiyama et al. (9) , who reported that these cells were not important for the development of liver fi brosis. Kupffer cells and infi ltrating bone marrow-derived macrophages are a crucial link between chronic infl ammation and liver fi brosis (29). However, diverse populations of macrophages are involved in promoting anti-infl ammatory effects, as well fi brolysis (29). Macrophage depletion has been shown to compromise fi brolysis during the regression of liver fi brosis (30).
Using bone marrow chimeric mice, the present study has demonstrated the migration of bone marrow-derived cells to the liver, particularly to the fi brous septa, during the development of cirrhosis. A small number of BMC participated in the generation of hepatocytes in chimeric mice submitted to a cirrhosis-inducing protocol. A few GFP ϩ hepatocytes were also found in chimeric mice and in BMC-transplanted mice chronically infected with explained by the fact that TGF-β 1, as well as being a known pro-fi brogenic cytokine because of its effect on myofi broblast proliferation and collagen production, it is also a very important anti-infl ammatory cytokine (35). In fact, this duality may explain the failure of TGF-β 1-signaling inhibitors in the treatment of other fi brotic diseases (35). It is possible that a modulation of pro-fi brotic macrophage subsets, rather than a direct modulation of the production of TGF-β 1, could explain our results. Studies using galectin-3-null mice treated with CCl 4 showed that galectin-3 may be required for TGF-β -mediated myofi broblast activation and ECM production (7) . Thus the marked reduction in galectin-3 expression after BMC transplantation suggests that the TGF-β -mediated pathway and, consequently, ECM deposition might be affected by transplanted BMC. Previous reports have shown the expression of MMP, which are associated with a reduction of liver fi brosis after cell transplantation, by bone marrowderived cells (19, 36) . It has also been reported previously that liver macrophages can recruit neutrophils during the recovery phase. These cells also express MMP, which promote fi brolysis (37). Although the present study did not fi nd alterations in MMP-9 and TIMP-1 gene expression levels among saline-and BMC-treated cirrhotic mice, it is possible that other MMP, such as MMP-13, may be involved in the increased fi brosis was found when unfractionated BMC were transplanted into mice that were still being injured by CCl 4 (33).
The reduction of fi brosis after BMC transplantation may be because of the modulatory effects exerted by the transplanted cells on non-parenchymatous liver cells. We observed a reduction in the total number of infl ammatory cells, including phagocytes. Moreover, in our chronic experimental model, there was a strong relationship between the amount of fi brous tissue and the numbers of galectin-3 ϩ cells, which were mostly F4/80 ϩ macrophages. Macrophages have been shown to be key modulator cells in fi brogenesis, because they produce a number of mediators, including galectin-3 (29). There is evidence that galectin-3 induces a variety of intracellular signaling pathways that lead to the proliferation of hepatic stellate cells (8) . This factor is an important activator of fi broblasts (6 -8) and plays a pro-fi brotic role by regulating myofi broblast activation during fi brogenesis (7) .
TGF-β 1, a cytokine that promotes fi brosis in many organs, is mainly produced by hepatic stellate cells and stimulates the production of ECM components (34). The present study did not fi nd any signifi cant differences in TGF-β 1 mRNA levels between saline-and BMC-treated groups. Similar results were obtained with protein assessment by enzyme-linked immunosorbent assays (ELISA) in liver fragments (data not shown). This could be Figure 7 . Reduced numbers of galectin-3 ϩ cells in livers of BMC-treated mice 2 months after therapy. Immunofl uorescence for galectin-3 detection (red) in 5-mm frozen liver slices of saline-treated (A) (400 ϫ ) and BMC-treated (B) (400 ϫ ) mice, counterstained with DAPI (blue) for nuclei visualization. Quantifi cation of galectin-3 ϩ cells in saline-treated and BMC-treated groups (C). Data represent the means Ϯ SEM of fi ve to eight animals/group. * * * P Ͻ 0.0001. process of fi brosis regression after cell transplantation (36,38).
In conclusion, the present study has established a mouse model of cirrhosis with morphologic characteristics similar to those found in human cirrhosis, and shown that transplanted BMC migrate to the liver, where they modulate infl ammation and fi brosis. The fi ndings of a reduction in fi brous tissue and low galectin-3 expression in animals submitted to cell transplantation reiterate the role this molecule plays in the development of fi brosis, and calls attention to its importance as a target for anti-fi brotic therapies. Additional studies attempting to understand BMC cell populations better and the mechanisms by which BMC transplantation ameliorates hepatic diseases should be conducted to develop successful clinical therapies for liver fi brosis.
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